Background
Mike Hinchey Lero

Lero – the Irish Software Research Centre (Lero) has been selected by the European Space Agency (ESA) for the implementation of a research programme worth €400,000. The 18 month programme, which will be led by Lero Director Prof. Mike Hinchey, will commence this month.

Lero will collaborate with chip manufacturer Cobham Gaisler AB of Gothenburg, Sweden on the software behind specialist microchips to be used in European space missions. The Cobham Gaisler  LEON radiation hardened microchip, which was developed in association with the European Space Agency, is designed to operate in harsh environments such as space.

Lero researchers based at the University of Limerick will work on a new back end for the Open Source LLVM compiler library to enable it to be used for the LEON chip family. This is designed to expand the toolset available to developers working on the flight software for future European space missions in order to boost reliability.

This is the third and largest contract awarded in recent years by the European Space Agency to Lero, which is backed by Science Foundation Ireland.

“We are honoured to be selected for this important work,” commented Prof Mike Hinchey, Director, Lero. “Software designed for space missions needs to be leading edge and highly reliable in view of the cost, distance and unforgiving environment involved.”

Before heading up Lero, Prof. Hinchey was Director of the Software Engineering Laboratory at NASA Goddard Space Flight Centre in Greenbelt, Maryland. He remains a consultant to NASA.

Lero (www.lero.ie) is a global leader in software engineering research. It combines the best in Irish software talent by bringing together researchers from Dublin City University, Dundalk Institute of Technology, NUI Galway, Trinity College Dublin, University College Cork, University College Dublin and University of Limerick. It is funded by Science Foundation Ireland as well as by contracts from Irish and international technology corporations.

Human Bone Marrow MSCs

NUI Galway has signed an agreement to formalise collaborative ties with the Mayo Clinic Centre for Regenerative Medicine in the US. The agreement follows many years of close cooperation, and paves the way for joint collaborations in clinical trials using regenerative therapies.

(You can check out REMEDI’s research in an upcoming episode of Series 3 of The Science Squad, due for broadcast this Autumn on RTE One)

Collaborative research projects will focus on a number of key strategic areas of importance for both institutes, including adult stem cell therapy, gene therapy, biomaterials and biomedical engineering. Furthermore, the agreement facilitates ongoing student and staff exchange between Galway and the US.

The Memorandum of Understanding (MOU) puts the emphasis on regulatory science to facilitate global translation of regenerative medicine therapies to the clinic. Both the National University Ireland Galway and the Mayo Clinic Centre for Regenerative Medicine have GMP cell manufacturing facilities, licensed for use by the respective national medical authorities.

National University of Ireland Galway’s President, Dr Jim Browne, welcoming the signing of the MOU, said: “Formalising our longstanding links paves the way for advancing our common agenda which is to realize the potential of regenerative medicine. Here in Galway we have Ireland’s only facility licenced to produce stem cells for human use, while the new clinical and translational research facility for conducting clinical trials with patients will be complete in early 2015.”

NUI Galway’s Regenerative Medicine Institute (REMEDI) and the Network of Excellence for Functional Biomaterials (NFB), both of which are supported by Science Foundation Ireland, are working together specifically to develop joint clinical trial programmes in the area of regenerative medicine.

Professor Tony Windebank, Deputy Director for Discovery of the Centre for Regenerative Medicine at Mayo Clinic said: “Mayo Clinic and NUI Galway have an established track record and commitment to regenerative medicine over the last decade. The Mayo Clinic has prioritized the development of new regenerative medicine clinical applications as a critical strategy for meeting the needs of patients in the future, which was evidenced in the formation of our Centre for Regenerative Medicine in 2012.”

The signing of the MOU comes on top of the recent announcement of a new $16 million agreement between Mayo Clinic and Enterprise Ireland where up to 20 novel medical technologies will be commercialised in Ireland over the next five years with the aim of creating several high value medical technology spin-out companies.

Video featuring Professor Tony Windebank, Deputy Director for Discovery of the Centre for Regenerative Medicine at Mayo Clinic https://www.youtube.com/watch?v=B98ci3iAknE

MichaelODywer

Researchers at the National University of Ireland Galway have identified an enzyme that has a key role in the spread and survival of blood cancer cells. The discovery, which focussed on the cancer multiple myeloma, has just been published by the internationally acclaimed journal, Blood.

Multiple myeloma is a cancer of the blood which results from an overproduction of plasma cells, the white blood cells that produce antibodies. It leads to problems such as anaemia, bone damage, kidney failure and elevated calcium levels. There are about 240 new cases of multiple myeloma diagnosed each year in Ireland.

The research team was led by Health Research Board (HRB) Clinician Scientist, Professor Michael O’Dwyer and Professor Lokesh Joshi of the University’s Glycoscience Group, which is supported by Science Foundation Ireland. The group studies the complex sugars which cover all cells in the human body, and many of the proteins in the bloodstream. Dr Siobhan Glavey, a medical doctor funded by the HRB, also had a key role lead in the study and was lead author on the paper.

HRB Clinician Scientist, Michael O Dwyer, Professor of Haematology at the National University of Ireland Galway says; “While treatments for multiple myeloma have improved over the last decade, and most patients are living longer, there is no cure. Our research is crucial because it sheds new light on the biology of multiple myeloma which could lead to new strategies to overcome resistance to treatment.”

“Working in close cooperation with Dr Irene Ghobrial from the Dana Farber Cancer Institute at Harvard in the US and colleagues from the Institute of Cancer Research in the UK, we focused on alterations in a process called glycosylation, a process whereby proteins and lipids are modified by specific sugars, because of its role in cell-cell interactions and the spread of cancer cells in the blood.”

“In essence, we have linked the overproduction of a specific enzyme called sialyltransferase to disease progression and worse outcomes in multiple myeloma. The increase in this enzyme activity causes a series of knock on effects; increasing glycosylation, which in turn increases the interaction of the cancer cells with receptors on the walls of blood vessels called selectins which then encourages their circulation, spread and retention in the bone marrow.”

“Our aim now is to prevent these interactions that cause the spread using specific enzyme and selectin inhibitors”.

Dr Graham Love, CEO of the HRB, commented on the importance of the research: “Understanding what causes multiple myeloma to progress, or generate worse outcomes, is the first step towards improving treatment. This discovery reinforces the transformational role our Clinician Scientists have in bringing real clinical questions to a research environment and delivering results back to the bedside.”

Space Enbio

Investment in 40 new projects to help transition high potential young talent to fully independent research leaders

Minister for Research and Innovation, Mr Seán Sherlock, T.D. has announced €23 million in new funding to help support 40 of Ireland’s most promising young research talent to become fully independent researchers. The funding which is being awarded by Science Foundation Ireland (SFI) will help ensure that Ireland’s most talented young researchers can be encouraged to remain in Ireland, while also helping to attract excellent young researchers from other countries to base themselves here.

Minister for Research and Innovation, Mr Seán Sherlock TD said:“Funding for researchers at the outset of their careers is an important element of the Government’s strategy for job creation in research and innovation under our Action Plan for Jobs. SFI’s funding schemes for early career researchers help ensure that excellent research with the potential for real economic and societal impact is properly supported in Ireland. Investment like this is important for Ireland’s developing international reputation for excellent research with impact. The 40 research projects being awarded by SFI today demonstrate the enormous talent and potential that exists among Ireland’s young researchers.”

The €23 million in funding delivered by the Department of Jobs, Enterprise and Innovation, through SFI’s Starting Investigator Research Grant (SIRG) and Career Development Award (CDA) Programmes will support researchers and post-graduate students working on projects in areas such as sustainable and renewable energy, cancer research, neurological disorders, immunology, microbiology, biotherapeutics and Wireless Networks.

Professor Mark Ferguson, Director General of SFI and Chief Scientific Adviser to the Government of Ireland, said:“Both of the programmes under which funding is being announced today will help promising young researchers to create and develop impactful careers here in Ireland and in turn enable the pursuit of scientific research that has potential economic and societal impact. These programmes are also an important factor in ensuring that Ireland can succeed in persuading top young scientific talent from abroad to base their research efforts here in Ireland.”

SFI’s Starting Investigator Research Grant (SIRG) provides support for excellent postdoctoral researchers who wish to take steps towards a fully independent research career, while the Career Development Award (CDA) aims to support early and mid-career researchers who already hold a salaried, independent research post and who are looking to expand their research activities. Both programmes aim to support the development of young researchers with the potential to become excellent, fully independent research leaders in their chosen fields.

The 40 research projects awarded funding today will be funded by SFI through 12 research bodies, as follows: Trinity College Dublin (5), National University of Ireland Galway (5), Royal College of Surgeons in Ireland (4), Dublin City University (4), University College Cork (4), University of Limerick (4), National University of Ireland Maynooth (3), University College Dublin (3), National Institute for Bioprocessing Research and Training (3), Teagasc (2), Tyndall National Institute (2) and Dublin Institute for Advanced Studies (1).

A further 12 projects were also deemed scientifically excellent by the International Review Panel and are on a reserve list to be funded by SFI, if budgets permit later in the year.

Examples of projects supported:

Orla O’Sullivan (Teagasc Food Research Centre, Cork) SIRG

Orla’s research focuses on microbial diversity in the gut. Microbial diversity is highest in a healthy gut and Orla’s research will investigate if it is possible to improve that diversity and in turn improve the overall health of individuals. The research will also examine whether alterations in diet and/or lifestyle can influence microbial diversity and function.  Orla’s ultimate goal is to inform the potential development of nutritional supplements that can help improve human health.

Stephen Dooley (University of Limerick) SIRG

Stephen’s research will focus on understanding ways that cleaner and more versatile energy sources can be developed from indigenous biomass resources, including plant matter.  His goal is to find ways that help ensure that Ireland imports less fossil energy by creating environmentally benign energy technologies, particularly for transportation. He hopes that his research can help achieve this by informing a deeper and predictive understanding of how indigenous biomass, in particular, can be harnessed.

Patrick Hayden (Dublin City University) SIRG

Patrick’s research will investigate techniques that could improve the quality of laser-powered high-precision measurement. High-precision measurements on the composition and uniformity of drugs are useful to the pharmaceutical industry to help perform quality control as drugs are developed and produced. One method to perform these measurements is by measuring light emitted from the surface of the drug when a laser pulse is focused on it. The process is known as laser-induced breakdown spectroscopy (LIBS) at short wavelengths and Patrick’s research aims to increase the efficiency of this process. The research could also have applications in other areas including archaeology and forensic science.

Aoife Morrin (Dublin City University) CDA

Aoife’s research aims to explore the potential for the analysis of skin in non-invasive or minimally invasive diagnostic approaches as an alternative to more invasive blood sampling. Skin is the largest human organ and contains rich analytical information related to a wide variety of medical conditions. Pressures on healthcare systems have resulted in a greater focus on enhanced efficacy of treatments and cost reduction. As such, there is a lot of research into new diagnostics that can address these challenges. Aoife intends her research to demonstrate innovative approaches to the analysis of skin that can be used for the early detection of various conditions including eczema flare-ups, liver failure, and skin cancer.

Alex von Kriegsheim (University College Dublin) SIRG

Alex’s research aims to develop new treatments to help prevent against bowel cancer in patients with colitis and Crohn’s disease. Both conditions lead to chronic inflammation of the gut, which can in turn increase the risk of bowel cancer. Alex hopes that his research can identify the ways in which this inflammation causes the growth of cancer cells and how the process can be halted through the release of important enzymes known as hydroxylases, which are blocked in chronically inflamed tissues.

Click Here for the list of Funded Projects

reellife-science-image-1

ReelLife Science, a novel Science video competition, was recently launched in 316 primary and secondary schools by a team of NUI Galway staff and students. The competition aims to involve school children in Science in a fun way, developing their analytical, creative and communication skills, while enabling NUI Galway researchers and students to engage in Outreach in an innovative manner.

The initiative was conceived by NUI Galway’s Dr Enda O’Connell, a winner of the inaugural ‘I’m a Scientist, Get me out of Here, Ireland” competition in November 2012, securing funding for a science communication project. Additional funding to expand the project was awarded by the NUI Galway Students’ Union EXPLORE Innovation Initiative and the College of Science.

Now supported by a team of NUI Galway Science communicators, ReelLife Science will award a total of €1000 in prizes, while winners will also be invited to attend the Galway Science and Technology Festival on Sunday, 24 November in NUI Galway, where their videos will be on display to the general public.

Short (1-3 min) videos may be submitted by the invited schools consisting of all primary and secondary schools in Galway, and the 28 schools which participated in ‘I’m a Scientist, get me out of here, Ireland’ 2012. Videos will be judged by a panel of internationally recognised scientists, including Professor Rhodri Ceredig, REMEDI, NUI Galway and Professor Andrea Brand of Gurdon Institute, Cambridge.

Emma Dalton, Science teacher and Transition Year Coordinator in St Enda’s College Galway, said of her students’ upcoming participation: “I am very excited, as this competition offers an opportunity for students to step away from the curriculum and engage in Science in a more fun way. It is also an opportunity for them to guide their own learning and then, even better, to practice sharing what they have learnt with others. I am really looking forward to seeing the ideas they come up with.”

The closing date for submissions is Friday, 25 October. The winning videos will be displayed on the projects website, www.reellifescience.com, Facebook page https://www.facebook.com/ReelLifeScience, and Twitter feed, @ReelLifeScience, where regular updates, Science news and blog posts can be found.

For further information visit www.reellifescience.com